Winston-Salem 12/11/2009 8:44:34 PM
News / Business

SmallCapReview.com - Stocks To Watch - AMCG, EMR, SPPI, AVCT

Amico Games Corp. (OTCBB: AMCG ) $0.65, Announced Thursday after market close that the completion of the first stage of development of a WAP 2.0 platform (Wireless Application Protocol) by Galaxy Software Ltd, the Chinese Company that Amico Games Corp. is set to acquire. The WAP 2.0 platform will, upon successful completion, greatly improve the gaming experience and performance of the WAP games developed by Galaxy Software.


Galaxy Software Ltd began migrating its mobile games to the WAP 2.0 platform in October 2009 and has now completed the first stage of this process. The overall project is estimated to be completed in July 2010.


"I am excited about the improvement in our WAP game performance with the completion of the first stage of the WAP 2.0 migration," Mr. Peter Liu, CEO and President of AMCG, commented. "We are committed to providing a better game playing experience to our users. Although the WAP 2.0 migration is not fully completed, our mobile games have achieved obvious improvements and users have provided us with a positive response. I am convinced that our WAP game will have a longer life span with our continuing efforts to improve the game playing experience."


What They Do: Amico Games Corp. is set to acquire a cutting edge interactive entertainment media company specializing in developing multi-player networked mobile phone games that are played over the mobile internet in China -- Galaxy Software Limited.


Galaxy Software Limited delivers its mobile phone games across JAVA and WAP platforms over 3G and 2.5G mobile telecommunication network in China. As of October 31, 2009, Galaxy's WAP game "Miracle Journey to the West" has accumulated around 15,000,000 registered users, taking up 11.1% share of multiplayer WAP game market, which is the market leader of the WAP game in terms of registered users.


Emerson (NYSE: EMR) $41.71, Today announced that it has successfully completed its tender offer for all of the outstanding shares of common stock of Avocent Corporation (Nasdaq: AVCT). The offer expired at 5 p.m. EST on Thursday, December 10, 2009. A total of approximately 43.2 million shares of Avocent common stock were tendered, representing approximately 97 percent of Avocent’s outstanding shares, including approximately 2.5 million shares tendered pursuant to a notice of guaranteed delivery. All shares validly tendered and not withdrawn have been accepted for payment by Emerson.


What They Do: Emerson is a global leader in bringing technology and engineering together to provide innovative solutions to customers through its network power, process management, industrial automation, climate technologies, and appliance and tools businesses.


What They Do: Avocent Corporation designs, manufactures, licenses, and sells software and hardware products and technologies that provide connectivity and centralized management of information technology infrastructure in the United States and internationally.


Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) $4.67. Today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.


Results: Fifty-one patients had completed the R-CHOP treatment and the overall response rate was 94.1% including 30 (58.8%) of patients in CR and 17 (35.3%) in PR. Treatment was well tolerated; grade 3-4 AEs are comparable with previous experience and the most common grade 3-4 AEs was neutropenia. At this time 47 patients had just received 90Y-IT and 45 are evaluable. In particular, 9/17 (52.9%) patients converted from PR to CR after treatment with 90Y-IT.


Conclusions: These preliminary data indicate that radioimmunotherapy appears highly effective and feasible as “consolidation” after 4 cycles of immunochemotherapy in elderly DLBCL patients, improving quality of response without any cumulative toxicity.


What They Do: Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a primary focus in oncology.


About SmallCapReview

Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview. SmallCapReview has been compensated three thousand five hundred dollars by a third party Green Horseshoe for it efforts in regards to Amico Games.